Inhibitory effect of tacrolimus on progression of joint damage in patients with rheumatoid arthritis

International Journal of Rheumatic Diseases

Volumn 17, Issue 7, 2014, Pages 749-754

  Motomura, Hiraku ^a   Matsushita, Isao ^a   Seki, Eiko ^a   Mine, Hayato ^a   Kimura, Tomoatsu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

mTSS; Joint damage; Rheumatoid arthritis; Tacrolimus

Indexed keywords

BUCILLAMINE; C REACTIVE PROTEIN; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; ANTIRHEUMATIC AGENT;

AGED; ARTICLE; CLINICAL ARTICLE; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HUMAN; JOINT INJURY; JOINT RADIOGRAPHY; MALE; MODIFIED TOTAL SHARP SCORE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; DRUG EFFECTS; JOINT; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; DISEASE PROGRESSION; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84914168157     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12227     Document Type: Article

References (28)

1. Scott LJ, McKeage K, Keam SJ, Plosker GL (2003) Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63 (12), 1247-97.
2. Ho S, Clipstone N, Timmermann L et al. (1996) The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 80 (3 Pt 2), S40-5.
3. Magari K, Miyata S, Ohkubo Y, Mutoh S (2004) Inflammatory cytokine levels in paw tissues during development of rat collagen-induced arthritis: effect of FK506, an inhibitor of T cell activation. Inflamm Res 53 (9), 469-74.
4. Sakuma S, Nishigaki F, Magari K et al. (2001) FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm Res 50 (10), 509-14.
5. Sakuma S, Kato Y, Nishigaki F et al. (2000) FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol 130 (7), 1655-63.
6. Miyazaki M, Fujikawa Y, Takita C, Tsumura H (2007) Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis. Clin Rheumatol 26 (2), 231-9.
7. Takayanagi H, Kim S, Koga T et al. (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3 (6), 889-901.
8. Nakamura Y, Takarada T, Kodama A, Hinoi E, Yoneda Y (2009) Predominant promotion by tacrolimus of chondrogenic differentiation to proliferating chondrocytes. J Pharmacol Sci 109 (3), 413-23.
9. Nishigaki F, Sakuma S, Ogawa T, Miyata S, Ohkubo T, Goto T (2002) FK506 induces chondrogenic differentiation of clonal mouse embryonic carcinoma cells, ATDC5. Eur J Pharmacol 437 (3), 123-8.
10. Dai W, Dong J, Fang T, Uemura T (2008) Stimulation of osteogenic activity in mesenchymal stem cells by FK506. J Biomed Materials Res Part A 86 (1), 235-43.
11. Tang L, Ebara S, Kawasaki S, Wakabayashi S, Nikaido T, Takaoka K (2002) FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell Biol Int 26 (1), 75-84.
12. Furst DE, Saag K, Fleischmann MR et al. (2002) Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 46 (8), 2020-8.
13. Kremer JM, Habros JS, Kolba KS et al. (2003) Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum 48 (10), 2763-8.
14. Morita Y, Sasae Y, Sakuta T, Satoh M, Sasaki T, Kashihara N (2008) Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study. Mod Rheumatol 18 (4), 379-84.
15. Arnett FC, Edworthy SM, Bloch DA et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (3), 315-24.
16. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1), 44-8.
17. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 66 (3), 407-9.
18. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39 (1), 34-40.
19. van der Heijde DM (1996) Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Bailliere's Clin Rheumatol 10 (3), 435-53.
20. Jusko WJ, Thomson AW, Fung J et al. (1995) Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 17 (6), 606-14.
21. Suzuki K, Saito K, Tsujimura S et al. (2010) Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J Rheumatol 37 (3), 512-20.
22. Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y (2008) Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 67 (3), 380-8.
23. Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S (2006) Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 54 (10), 3119-25.
24. Smolen JS, Han C, van der Heijde DM et al. (2009) Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 68 (6), 823-7.
25. Young-Min S, Cawston T, Marshall N et al. (2007) Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 56 (10), 3236-47.
26. Houseman M, Potter C, Marshall N et al. (2012) Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther 14 (1), R30.
27. Kawai S, Takeuchi T, Yamamoto K, Tanaka Y, Miyasaka N (2011) Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial. Mod Rheumatol 21 (5), 458-68.
28. Naniwa T, Watanabe M, Banno S, Maeda T (2009) Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies. Rheumatol Int 29 (11), 1287-91.